1. Home
  2. BEAM vs NHC Comparison

BEAM vs NHC Comparison

Compare BEAM & NHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • NHC
  • Stock Information
  • Founded
  • BEAM 2017
  • NHC 1971
  • Country
  • BEAM United States
  • NHC United States
  • Employees
  • BEAM N/A
  • NHC N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • NHC Hospital/Nursing Management
  • Sector
  • BEAM Health Care
  • NHC Health Care
  • Exchange
  • BEAM Nasdaq
  • NHC Nasdaq
  • Market Cap
  • BEAM 1.9B
  • NHC 1.6B
  • IPO Year
  • BEAM 2020
  • NHC N/A
  • Fundamental
  • Price
  • BEAM $20.62
  • NHC $93.99
  • Analyst Decision
  • BEAM Strong Buy
  • NHC
  • Analyst Count
  • BEAM 11
  • NHC 0
  • Target Price
  • BEAM $48.90
  • NHC N/A
  • AVG Volume (30 Days)
  • BEAM 2.6M
  • NHC 66.2K
  • Earning Date
  • BEAM 08-05-2025
  • NHC 08-08-2025
  • Dividend Yield
  • BEAM N/A
  • NHC 2.69%
  • EPS Growth
  • BEAM N/A
  • NHC 31.05
  • EPS
  • BEAM N/A
  • NHC 6.91
  • Revenue
  • BEAM $63,578,000.00
  • NHC $1,374,458,000.00
  • Revenue This Year
  • BEAM N/A
  • NHC N/A
  • Revenue Next Year
  • BEAM $17.18
  • NHC N/A
  • P/E Ratio
  • BEAM N/A
  • NHC $13.84
  • Revenue Growth
  • BEAM N/A
  • NHC 18.19
  • 52 Week Low
  • BEAM $13.53
  • NHC $89.14
  • 52 Week High
  • BEAM $35.25
  • NHC $138.49
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 55.12
  • NHC 26.53
  • Support Level
  • BEAM $19.40
  • NHC $93.54
  • Resistance Level
  • BEAM $22.76
  • NHC $99.95
  • Average True Range (ATR)
  • BEAM 1.32
  • NHC 2.52
  • MACD
  • BEAM -0.01
  • NHC -0.96
  • Stochastic Oscillator
  • BEAM 38.07
  • NHC 3.40

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About NHC National HealthCare Corporation

National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services, and Home care hospice services. Generating, a majority of its revenue from Inpatient services.

Share on Social Networks: